Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

RayzeBio Inc., a San Diego-based company that is building a large factory on the northwest side of Indianapolis to make radioisotopes for cancer treatment, has agreed to be acquired by ...

RayzeBio is also building the infrastructure for producing its radiopharmaceuticals. The company has budgeted about $40 million for completing construction of a manufacturing facility in Indianapolis.

RayzeBio currently has 88 employees, 77 of whom are in research and development. The company said about 64 people will work in the Indianapolis plant , where the jobs will pay an average of $44 an ...

Bristol Myers Squibb's $4.1 billion bid for RayzeBio was enough to beat ... The acquisition also includes RayzeBio’s almost-complete “state-of-the-art” manufacturing facility in Indianapolis.

RayzeBio also hopes to use some of the IPO haul to finish construction of a GMP manufacturing facility in Indianapolis, the company said in the filing.

It may have been a day late, but Bristol Myers Squibb (BMY -2%) gave RayzeBio (RYZB +101%) investors a nice stocking stuffer today. BMY will acquire RayzeBio for $62.50 per share in cash, for a total ...

Bristol Myers Squibb on Tuesday announced a deal to acquire RayzeBio in an effort to expand the drugmaker’s cancer treatment offerings. The acquisition was for a total equity value of about $4.1 ...

In an effort to expand its cancer treatment offerings, Bristol Myers Squibb plans to acquire RayzeBio, a radiopharmaceutical therapeutics company. The deal is worth $4.1 billion, the companies ...

Drug company Bristol-Myers Squibb BMY 0.26 % increase; green up pointing triangle struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology.